Yahoo奇摩 網頁搜尋

搜尋結果

  1. Recruiting加入高端疫苗. 我們重視員工的成長、發展與工作熱情,. 誠摯地歡迎具專業能力與創新思考的您,一起努力為人類健康做出貢獻!. 加入我們. 地 址302 新竹縣竹北市生醫三路68號. 電 話03-668-4866. 傳 真03-668-4865. E-mailinfo@medigenvac.com. 關於高端.

  2. 2024年1月9日 · 疫苗公司股價在此期間大幅波動現象,國內外皆然。 有關高端新冠疫苗採購合約是否公開。 本公司於今日 (1/9) 收到衛福部疾管署來函公文,建請本公司同意提早解除有關新冠疫苗緊急採購之保密合約。

  3. 高端腸病毒71型疫苗取得台灣食藥署藥品許可證,預計供貨時間為今年第三季起。 本公司腸病毒71型疫苗通過新藥查驗登記核准,三期臨床試驗驗證疫苗有效性達96.8%,並發表於The Lancet刺胳針。 READ MORE

  4. 2021/07/19MVC COVID-19 Vaccine Obtains Taiwan EUA Approval. TAIPEI, TAIWAN --July 19th, 2021. Medigen Vaccine Biologics Corp (MVC) obtains Taiwan EUA approval due to MVC's COVID-19 vaccine has fulfilled following EUA standards set by Taiwan's regulatory agencies: 1.For the GMT of MVC-COV1901, the lower bound of 95% confidence interval (CI) is 3 ...

  5. TAPEI, TAIWAN and EMERYVILLE, CA - October 13, 2020 - Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that MVC has obtained a ...

  6. 最新消息. 2021/01/25高端新冠肺炎疫苗第二期試驗,已進行受試者收案與疫苗施打. 高端疫苗之MVC-COV1901新冠肺炎疫苗開發案,已於2020/12/29取得台灣衛福部第二期臨床試驗核准函,開始進行受試者招募,日前於各試驗醫院開始進行受試者疫苗施打。. MVC-COV1901新冠 ...

  7. MVC obtained TPEX's (Taipei Exchange) approval for listing on Taiwan OTC Exchange (TWO) on December 22nd. MVC focuses on developing novel vaccines including EV71 vaccine, H7N9 mock-up vaccine, and Dengue vaccine and applied for TWO approval as